![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Peter MacCallum Cancer Centre, Australia Celgene Corporation |
---|---|
Information provided by: | Peter MacCallum Cancer Centre, Australia |
ClinicalTrials.gov Identifier: | NCT00434239 |
This study is mainly assessing the safety of Revlimid in combination with Ancestim (recombinant human stem cell factor) in patients with symptomatic myelodysplasia. Of those two compounds, Revlimid has been shown to be an active drug in myelodysplasia. Clinical responses will also be assessed.
Condition | Intervention | Phase |
---|---|---|
Myelodysplasia |
Drug: Lenalidomide + Ancestim |
Phase 0 |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Pilot Study of the Combination of Lenalidomide (Revlimid®) With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor (rhSCF; Ancestim) for Myelodysplasia. |
Estimated Enrollment: | 25 |
Study Start Date: | February 2007 |
Estimated Study Completion Date: | February 2010 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Aim: The primary objective is to assess the safety of Revlimid in combination with Ancestim in patients with symptomatic myelodysplasia. The secondary objectives are: Duration of response and assessment of changes in gene expression profile of bone marrow samples from patients undergoing such treatment.
Potential Significance: Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders. Prognosis can be estimated by use of the International Prognostic Scoring System (IPSS) which divides patients into low, intermediate-1, intermediate-2, and high-risk groups with corresponding median survival times of 5.7 years, 3.5 years, 1.2 years, and 0.4 years, respectively. There is currently no standard treatment for MDS and management is often purely symptomatic with transfusion of blood products and antibiotic treatment of infections.
A recent phase II study however has shown significant response rates with Revlimid as a single agent in patients with MDS. The total response rate was 56%. The effects of Revlimid and SCF on hematopoietic progenitors cells were examined in vitro. RhSCF and Revlimid were shown to be synergistic in stimulating the proliferation of hematopoietic progenitor cells and their precursors in vitro, thereby forming the rationale for this study.
Research Plan: This is a single-centre, open label, single-arm, non-comparative study, in which 25 patients will be enrolled. The study will include patients who meet all the inclusion and none of the exclusion criteria, as per the respective protocol section.
The patients will be enrolled sequentially to receive 2 different dose levels of Ancestim with a fixed dose of Revlimid. This will determine the feasibility and tolerability of the combination of Revlimid and Ancestim. Patients will start with an 8 week course of single agent Revlimid as 10mg daily oral treatment day 1-21 in a 28 day cycle. If patients do not achieve a complete remission on single agent Revlimid they will start on Ancestim s.c. injections. Two dose levels of Ancestim (10 and 20 mcg/kg s.c. daily for 7 days) will be evaluated.
Safety: Safety will be assessed by the reporting of adverse events (starting with the first study-related procedure, during treatment, and for a period of 60 days following discontinuation of treatment). The intensity of the adverse events will be assessed using National Cancer Institute common toxicity criteria. All adverse events will be recorded on the case report forms (CRFs). Furthermore, assessments of physical (including neurological / peripheral neurological) examinations, vital signs measurements, and haematology and clinical chemistry tests will be used to monitor safety. Clinically relevant changes in laboratory safety tests, vital signs, and physical examinations will be recorded as adverse events. The adverse event sections of the CRFs will be submitted to a representative of the sponsor at the end of each treatment cycle. Serious adverse events will be reported as they occur, on forms provided by the sponsor.
Efficacy: Response to treatment will be assessed according to the guidelines of the international working group to standardize response criteria for myelodysplastic syndromes. This will be done on bone marrow biopsies (including cytogenetic analyses) and peripheral blood counts. An additional scientific investigation will examine gene-expression profiles of bone-marrow and blood samples at different time points and will try to correlate those with response to treatment. Concomitant in-vitro studies will assess surrogate markers of response.
Statistical Methods: Adverse events, serious adverse events, transfusion requirements, response data and Karnofsky performance status data will be summarized.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The patients must have either:
Exclusion Criteria:
Contact: Miles Prince, Prof. | +61-3-9656 ext 1700 | Miles.Prince@petermac.org |
Contact: Melita Kenealy, Dr. | +61-3-9656 ext 1111 | melita.kenealy@petermac.org |
Australia, Victoria | |
Peter MacCallum Cancer Centre | Recruiting |
East Melbourne, Victoria, Australia, 3002 |
Principal Investigator: | Miles Prince, Prof. | Peter MacCallum Cancer Centre, Australia |
Responsible Party: | Peter MacCallum Cancer Centre ( Miles Prince ) |
Study ID Numbers: | 06/49 |
Study First Received: | February 11, 2007 |
Last Updated: | August 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00434239 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
Myelodysplasia Lenalidomide Ancestim Pilot trial Biomarkers |
Myelodysplastic syndromes Neural Tube Defects Preleukemia Precancerous Conditions Nervous System Malformations Hematologic Diseases |
Myelodysplasia Myelodysplastic Syndromes Lenalidomide Neural tube defect, folate-sensitive Congenital Abnormalities Bone Marrow Diseases |
Neoplasms Antineoplastic Agents Therapeutic Uses Nervous System Diseases Pharmacologic Actions |